|Bid||79.32 x 800|
|Ask||79.33 x 1000|
|Day's Range||78.34 - 79.52|
|52 Week Range||74.13 - 147.17|
|PE Ratio (TTM)||21.77|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||115.73|
NEW YORK, NY / ACCESSWIRE / May 25, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Celgene Corporation ("Celgene" or the "Company") (CELG) and certain of its officers, on behalf of shareholders who purchased Celgene securities between January 12, 2015 and February 27, 2018, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is an FDA-approved drug designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease in pediatric patients and adults. Biogen (BIIB), which has held the worldwide development and commercialization rights for Spinraza since January 2012, forwards royalties to Ionis.
Celgene is opening its wallet yet again, but to what end? The struggling biotech giant announced Thursday that it plans to spend $2 billion on an accelerated stock repurchase. Celgene’s shares rose early Thursday as they typically do after such announcements, but the pace of Celgene’s buybacks shouldn’t do much to reassure investors.
Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired the securities of Celgene Corporation (“Celgene” or the “Company”) (CELG) between September 12, 2016 and February 27, 2018, inclusive (the “Class Period”). Celgene investors have until May 29, 2018 to file a lead plaintiff motion. To obtain information or actively participate in the class action, please visit Celgene page on our website at www.glancylaw.com/case/celgene-corporation.
In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.
Moody's Investors Service commented that the $2 billion accelerated share repurchase program announced by Celgene Corporation ("Celgene") is credit negative. There is no impact on the company's ratings including the Baa2 senior unsecured long-term rating and the Prime-2 commercial paper rating or stable rating outlook. For additional information please refere to Moody's issuer comment on Celgene available on www.moodys.com.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, and other biotechnology assets traded slightly higher Wednesday after the U.S. House of Representatives on Tuesday passed “right to try” legislation. IBB tracks the Nasdaq Biotechnology Index and holds nearly 160 stocks.
Celgene and General Electric were leaders in Thursday's mixed open, as investors sorted news of new tariffs, and a third straight drop in oil prices.
rose in premarket trading on Thursday, May 24, after the biotech firm said its board had authorized an additional $3 billion of stock buybacks. The Summit, N.J.-based company also said it plans to enter into an accelerated share repurchase agreement (ASR) to buy back $2 billion of stock. "The increase in our share repurchase authorization and planned accelerated share repurchase program reflects our confidence in the long-term potential of Celgene," said Celgene chairman and CEO Mark J. Alles in a statement.
Celgene Corp. shares jumped 1.2% in premarket trade Thursday, after the company announced an additional $3 billion share buyback authorization. The biotech company said it will execute a $2 billion accelerated ...
Celgene Corporation (CELG) today announced that the Company's Board of Directors authorized the repurchase of an additional $3 billion of the Company's common stock. In addition, the Company plans to enter into an accelerated share repurchase (ASR) agreement to repurchase an aggregate of $2 billion of the Company’s common stock. The planned ASR will utilize part of the existing Board authorized share repurchase program as well as part of the new authorization.
Wall Street was split Wednesday on Celgene as one sell-side analyst downgraded the stock saying it "has tilted to greater risk" while another upgraded shares.
NEW YORK, May 23, 2018-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors ...
It's been two years since David's picked a batch of stocks made to thrive in a global society that's ever more focused on the life of the mind.
Bernstein analyst Aaron Gal upgraded Celgene from Market-Perform to Outperform and cut the price target from $121 to $102. By Bernstein’s assessment, Celgene’s current discounted cash flow reflects the worst possible outcome for the Revlimid trial — a result that could push the launch to April 2020. Toung is less optimistic about Revlimid’s legal issues, which could increase share volatility with an adverse ruling.
Celgene Corp. sell-side analysts can’t agree on what’s next for the company with shares hovering near a four-year low. Argus analyst David Toung moved to the sidelines on a risk-reward that has “tilted to greater risk” given an over-reliance on one of the world’s biggest brand-name cancer treatments, Revlimid. Shares tumbled on Monday to a four-year low after a news article about the departure of its former business development head, George Golumbeski, added gasoline to the fire of concerns for the drugmaker.
The reaction to news from Celgene and Insys demonstrates an undeniable truth: Mr. Market can be very irrational at times.
Law Offices of Howard G. Smith reminds investors of the May 29, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Celgene Corporation (“Celgene” or the “Company”) (NASDAQ: CELG) securities between January 12, 2015 and February 27, 2018, inclusive (the “Class Period”). Celgene investors have until May 29, 2018 to file a lead plaintiff motion.
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Celgene Corporation (“Celgene” or the “Company”) (CELG) of the May 29, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Celgene stock or options between September 12, 2016 and February 27, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/CELG. There is no cost or obligation to you.
Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.
After years of growth, Celgene Corporation (NASDAQ:CELG) has spent the past eight months suffering from ever-weakening price action. In fact and with shares of Celgene now off a full 50% from 2017’s all-time-highs following Monday’s 4.70% price drop, you could say bears have been acting with barely any hesitation in CELG stock. The latest ‘disappointment’ in shares of Celgene, judging by Monday’s price reaction, is a report that Celgene’s top dog of business development discreetly retired over a month ago.
NEW YORK, May 22, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Celgene Corporation between January ...